Roche Holding Valuation

Q: What is the Fair Price of ROZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ROZ (CHF287) is trading below our estimate of [[fair value]] (CHF788.48)

Is ROZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ROZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

CHF 788.48

Fair Value

63.6% undervalued

Number of Analysts

Below Fair Value: ROZ (CHF287) is trading below our estimate of fair value (CHF788.48)

Significantly Below Fair Value: ROZ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ROZ?

Key metric: As ROZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ROZ. This is calculated by dividing ROZ's market cap by their current earnings.
What is ROZ's PE Ratio?
PE Ratio	20x
Earnings	CHF 10.62b
Market Cap	CHF 215.01b

ROZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.1x
Enterprise Value/EBITDA	11.7x
PEG Ratio	2x

Price to Earnings Ratio vs Peers

How does ROZ's PE Ratio compare to its peers?

The above table shows the PE ratio for ROZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	22.5x
AZN AstraZeneca	32x	16.8%	UK£170.3b
GSK GSK	21.9x	20.4%	UK£55.1b
HIK Hikma Pharmaceuticals	19.2x	11.0%	UK£4.5b
NOVN Novartis	16.9x	7.2%	CHF 182.1b
ROZ Roche Holding	20x	10.3%	CHF 215.0b

Price-To-Earnings vs Peers: ROZ is good value based on its Price-To-Earnings Ratio (20x) compared to the peer average (22.5x).

Price to Earnings Ratio vs Industry

How does ROZ's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: ROZ is good value based on its Price-To-Earnings Ratio (20x) compared to the European Pharmaceuticals industry average (20.1x).

Price to Earnings Ratio vs Fair Ratio

What is ROZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ROZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	20x
Fair PE Ratio	36.3x

Price-To-Earnings vs Fair Ratio: ROZ is good value based on its Price-To-Earnings Ratio (20x) compared to the estimated Fair Price-To-Earnings Ratio (36.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target

Consensus Narrative from 18 Analysts

CHF 325.72

Fair Value

11.9% undervalued

Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 06:50
End of Day Share Price	2025/01/10 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Roche Holding AG is covered by 58 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamla Singh	AlphaValue
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research